AbstractThe clinical data on the efficacy and toxicity of bortezomib as treatment for multiple myeloma patients are restricted to prospective phase II studies in expert myeloma centers. Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refractory multiple myeloma who were treated in community centers in a compassionate need program.
Figures & Tables
Vol. 90 No. 7 (2005): July, 2005 : Clinical Trial
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com